Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). | A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus HF10 for unresectable locally advanced pancreatic cancer